LadRx Corp Files Q2 2024 10-Q

TL;DR

LadRx Corp (LADX) filed its Q2 10-Q. Check financials.

AI Summary

LadRx Corp filed its 10-Q for the period ending June 30, 2024. The company, formerly known as CYTRX CORP, is in the biological products sector and is incorporated in Delaware. Its principal executive offices are located in Los Angeles, California.

Why It Matters

This filing provides investors with an update on LadRx Corp's financial performance and operational status for the second quarter of 2024.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags.

Key Players & Entities

• LadRx Corp (company) — Filer
• CYTRX CORP (company) — Former company name
• 20240630 (date) — Period of report
• 20240814 (date) — Filing date
• 11726 SAN VICENTE BOULEVARD (address) — Business and mailing address
• LOS ANGELES (location) — City of business address
• DE (location) — State of incorporation

FAQ

Key Financial Figures

• $1 million — ed to receive (i) a one-time payment of $1 million upon acceptance of a re-submission of a
• $1.0 million — ry 2024 recognized such net proceeds of $1.0 million as other income in the statement of ope

Filing Documents

• form10-q.htm (10-Q) — 557KB
• ex31-1.htm (EX-31.1) — 8KB
• ex31-2.htm (EX-31.2) — 8KB
• ex32-1.htm (EX-32.1) — 5KB
• ex32-2.htm (EX-32.2) — 5KB
• 0001493152-24-031792.txt ( ) — 2937KB
• ladx-20240630.xsd (EX-101.SCH) — 21KB
• ladx-20240630_cal.xml (EX-101.CAL) — 28KB
• ladx-20240630_def.xml (EX-101.DEF) — 102KB
• ladx-20240630_lab.xml (EX-101.LAB) — 213KB
• ladx-20240630_pre.xml (EX-101.PRE) — 163KB
• form10-q_htm.xml (XML) — 364KB

Financial Statements (unaudited)

Financial Statements (unaudited) 4 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3. Quantitative and Qualitative Disclosures About Market Risk 21 Item 4. Controls and Procedures 21 PART II. — OTHER INFORMATION 21 Item 1. Legal Proceedings 21 Item 1A Risk Factors 21 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosures 21 Item 5. Other Information 21 Item 6. Exhibits 21

SIGNATURES

SIGNATURES 22 INDEX TO EXHIBITS 23 2 Forward Looking Statements All regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "could" or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, the factors discussed in this section and under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"), which should be reviewed carefully. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no o

View Full Filing

View this 10-Q filing on SEC EDGAR